Investigating a signaling pathway involved in systemic sclerosis
EphB/EphrinB signaling in Systemic Sclerosis
This study is looking at how certain proteins in the body might help stop skin damage and thickening in people with systemic sclerosis, and it hopes to find new ways to treat this condition by understanding how these proteins work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10898707 on NIH RePORTER |
What this research studies
This research focuses on the EphB2 receptor and its EphrinB ligands as potential targets to prevent vascular damage and fibrosis in systemic sclerosis (SSc), a condition characterized by excessive collagen deposition in the skin. By studying human skin biopsies and mouse models, the researchers aim to understand how these signaling molecules contribute to the disease process. The goal is to uncover the biochemical pathways that lead to the transformation of skin cells into fibrogenic cells, which exacerbate fibrosis. This could lead to new therapeutic strategies for managing SSc.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic sclerosis who are experiencing skin fibrosis.
Not a fit: Patients with other autoimmune diseases that do not involve skin fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reduce skin fibrosis in patients with systemic sclerosis.
How similar studies have performed: Previous research has shown promising results in targeting similar signaling pathways for fibrosis in other organs, suggesting potential for success in this area as well.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Mimche, Patrice — University of Utah
- Study coordinator: Mimche, Patrice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.